Q1 2024 · 13F-HR
ARCH Venture Management, LLCholdings as filed
Filed 2024-05-15 · accession 0001012975-24-000230
$80.3M
Reported value
8
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 92539P101 | — | VERVE THERAPEUTICS, INC. | $26.7M | 33.2% | 2,008,809 | Common | NONE |
| 29479A108 | ERAS | ERASCA, INC. | $22.8M | 28.4% | 11,055,554 | Common | NONE |
| 38341P102 | GOSS | GOSSAMER BIO, INC. | $9.5M | 11.8% | 8,055,916 | Common | NONE |
| 24823R105 | DNLI | DENALI THERAPEUTICS, INC. | $7.8M | 9.75% | 381,249 | Common | NONE |
| 746964105 | QTTB | Q32 BIO INC. | $5.5M | 6.80% | 320,482 | Common | NONE |
| 71902K105 | — | CERO THERAPEUTICS HOLDINGS, INC. | $4.4M | 5.52% | 1,444,296 | Common | NONE |
| 82933R100 | — | SINGULAR GENOMICS SYSTEMS, INC. | $2.0M | 2.43% | 3,798,926 | Common | NONE |
| 91381U200 | UNBX | UNITY BIOTECHNOLOGY, INC. | $1.6M | 2.05% | 1,004,817 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.